B-cell receptor (BCR) signaling, crucial to normal B-cell survival and development, also remains active in most lymphomas and certain leukemias, either as a function of self-antigen engagement in the tumor microenvironment or through mechanisms that leave the BCR constitutively activated and antigen-independent. This evidence concerns the gene BCR and lymphoma.